Abstract:
Cutaneous leishmaniasis is the most common form of leishmaniasis. It is a skin infection
caused by a single-celled parasite that is transmitted by sand fly bites. Although the cutaneous
form of the disease is often self-limiting, it does result in significant scarring and can spread
to more invasive, mucocutaneous disease. Leishmaniasis is endemic in 88 countries on five
continents. The pentavalent antimonials meglumine antimonate (85 mg Sb/mL) for
intramuscular administration and sodium stibogluconate (100 mg Sb/mL) for intravenous and
intramuscular administration have been used for decades for the treatment of New World
cutaneous leishmaniasis, and are the gold standard for other new investigational drugs.
Cutaneous leishmaniasis has been treated in patients of all ages with a wide range of physical
methods, including cauterization, surgical excision, cryotherapy and the application of local
heat. The antibacterial activity of proteinase was determined against different types of
bacteria isolated from patients and healthy individuals. The most sensitive bacteria were
Lactobacillus spp. While Pseudomonas aeruginosa is the most resistant. Candidal proteinase,
also have an anti-leishmania donovani activity ( on the promastigote stage)[15] . Thus this
study was conducted to evaluate the effect of proteinase enzyme on promastigote stage of L.
tropica, in vitro and the possibility to be used in the future as an anti-leishmanial drug.
